In vitro activity of gemifloxacin against recent clinical isolates of bacteria in Korea.
Gemifloxacin is an enhanced-affinity fluoroquinolone with broad-spectrum antibacterial activity. In Korea, resistant bacteria are relatively more prevalent than in other industrialized countries. In this study, we studied the in vitro activities of gemifloxacin, gatifloxacin, moxifloxacin, levofloxacin, ciprofloxacin, and other commonly used antimicrobial agents against 1,689 bacterial strains isolated at four Korean university hospitals during 1999-2000. Minimum inhibitory concentrations (MICs) were determined using the agar dilution method of National Committee for Clinical Laboratory Standards. Gemifloxacin had the lowest MICs for the respiratory pathogens: 90% of Streptococcus pneumoniae, Moraxella catarrhalis, and Haemophilus influenzae were inhibited by 0.06, 0.03, and 0.03 mg/L, respectively. Gemifloxacin was more active than the other fluoroquinolones against methicillin-susceptible Staphylococcus aureus, coagulase-negative staphylococci, streptococci, and Enterococcus faecalis. The MIC90s of gemifloxacin for Klebsiella oxytoca, Proteus vulgaris, and non-typhoidal Salmonella spp. were 0.25, 1.0, and 0.12 mg/L, respectively, while those for other Gram-negative bacilli were 4-64 mg/L. In conclusion, gemifloxacin was the most active among the comparative agents against Gram-positive species, including respiratory pathogens isolated in Korea.
Yong
Dong Eun
DE
Department of Clinical Pathology and Research Institute of Bacterial Resistance, Yonsei University College of Medicine, Korea. infect@cmc.cuk.ac.kr
Cheong
Hee-Jin
HJ
Kim
Yang Soo
YS
Park
Yeon Joon
YJ
Kim
Woo-Joo
WJ
Woo
Jun Hee
JH
Lee
Kyung Won
KW
Kang
Moon Won
MW
Choo
Youn-Sung
YS
D000890:Anti-Infective Agents / Q000627:therapeutic use*; D001372:Aza Compounds; D001419:Bacteria / Q000187:drug effects*; D002939:Ciprofloxacin / Q000627:therapeutic use; D024841:Fluoroquinolones; D000077734:Gatifloxacin; D000077735:Gemifloxacin; D006193:Haemophilus influenzae / Q000187:drug effects; D007723:Korea; D064704:Levofloxacin; D008826:Microbial Sensitivity Tests; D009016:Moraxella / Q000187:drug effects; D000077266:Moxifloxacin; D009287:Naphthyridines / Q000627:therapeutic use*; D015242:Ofloxacin / Q000627:therapeutic use; D011804:Quinolines; D013296:Streptococcus pneumoniae / Q000187:drug effects
D000890:Anti-Infective Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D009287:Naphthyridines; D011804:Quinolines; D002939:Ciprofloxacin; D064704:Levofloxacin; D015242:Ofloxacin; D000077734:Gatifloxacin; D000077735:Gemifloxacin; D000077266:Moxifloxacin